Loading...
•
Mar 31, 2025
Twist Bioscience Q2 2025 Earnings Report
Twist Bioscience reported its Q2 2025 financial results with improved margins and narrowing losses.
Key Takeaways
Twist Bioscience delivered $92.8 million in revenue for Q2 FY25, with a significant improvement in gross margin to 49.6% and a reduced adjusted EBITDA loss of $14.8 million, indicating strong progress toward profitability.
Revenue reached $92.8M, at the top end of guidance.
Gross margin rose to 49.6%, showing strong operational improvement.
Adjusted EBITDA loss narrowed to $14.8M, trending toward breakeven.
All segments reported double-digit YoY revenue growth.
Revenue by Segment
Forward Guidance
Twist projects revenue growth in Q3 and Q4 FY25, aiming to surpass 50% gross margin and continue reducing EBITDA losses.
Positive Outlook
- Q3 FY25 revenue projected between $94M–$97M
- Gross margin expected to exceed 50% in Q4 FY25
- Strong NGS performance to continue
- Biopharma revenue expected to reach $6M
- Full-year revenue guided to $372M–$379M
Challenges Ahead
- Adjusted EBITDA still forecast to remain negative
- High SG&A expenses remain a drag on profitability
- Gross margin in Q3 may be below 50%
- Macroeconomic risks and R&D investments may affect cash burn
- Profitability timeline dependent on execution of margin expansion plans
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...